Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Aiforia Technologies

1.80 EUR

-2.17 %

2,176 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

-2.17 %
-7.46 %
-27.71 %
-21.05 %
-40.98 %
-50.68 %
-56.83 %
-
-64.43 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
60.64M EUR
Turnover
116.19K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
09.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
2.4.
2026

General meeting '26

28.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
CEO buying, 6,341 shares: Aiforia Technologies Oyj – Johdon liiketoimet – Jukka Tapaninen | Kauppalehti
3/11/2026, 2:42 PM
by NukkeNukuttaja
32
Inderes Aiforia Technologies Oyj – Johdon liiketoimet – Tuomas Tenkanen - Inderes Aiforia Technologies Oyj, Yhtiötiedote, Johtohenkilöiden liiketoimet 12.3.2026 klo 13.00Aiforia Technologies Oyj – Johdon liiketoimet – Tuomas Tenkanen Aiforia Technologies Oyj:n hallituksen... Tenkanen...
yesterday
by Critter
27
Digital Pathology Place Pathology Meets AI: Combining Veterinary and Medical Pathology for Digital... In this episode, I spoke with Dr. Richard Doughty, Senior Medical Advisor at Aiforia Technologies, who brings a rare combination of expertise as both a Est. reading time: 51 minutes...
yesterday
by Salvelinus
14
In my opinion, the CEO’s purchase signals to the market that “we are not planning a share issue anytime soon,” in addition to the fact that the stock can be interpreted as trading below the fair value estimated by the CEO. (If a share issue were being planned for the very near future...
yesterday
by JusaVaan
10
My rough estimate is that The 12/2025 additional funding, together with this year’s savings, will last until max Q4/2026. The 2025 net result was -12.7M EUR; since part of that is depreciation, R&D investments were +6M EUR. I would roughly estimate the cash burn to be at a level ...
yesterday
by Pekka
6
So, keeping in mind the high gross margin, we could perhaps for this reason subtract one million from the 2026 cash burn estimate, and another from that small cost-cutting program carried out at the end of last year. This means they could get by with a 9 million burn in 2026.
yesterday
by Puutaheinää
4
Here is some further clarification regarding revenue recognition, which at least previously was a bit unclear to me. Accounts receivable have grown quite a bit since last year.
yesterday
by Jekkku
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.